← Back to patent-cliff list
FLD-103
Tier C — Watch / tradeFLD-103
Feldan Therapeutics
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
-
Type
Targets：GLI1
Indications (approved)：Basal cell carcinoma
Regional status
US
Phase I
2024-10-30
EU
-
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of FLD-103?
Approved indications include: Basal cell carcinoma.
When does the FLD-103 patent expire?
No public expiry year is available for FLD-103 yet; this page updates once verified.
How do I get a quote for FLD-103 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-01